GERN — GERON CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886744 ·
Last close
$1.23
Market Cap
$787.03M
52W High
$2.01
52W Low
$1.04
ADV30
10,333,039
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 57,480,000 | 48,240,000 | -12,653,000 | -16,680,000 | 519,009,000 | 62,643,000 | 300,395,000 |
| Mar 2026 | 51,837,000 | 50,145,000 | -236,000 | -3,642,000 | 534,120,000 | 68,895,000 | 305,012,000 |
| Dec 2025 | 48,015,000 | 46,709,000 | -8,508,000 | -28,862,000 | 570,540,000 | 77,560,000 | 344,668,000 |
| Sep 2025 | 47,227,000 | 46,184,000 | -13,887,000 | -18,428,000 | 567,382,000 | 78,117,000 | 318,675,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-125,964,000
Investing CF
$106,664,000
Financing CF
$4,436,000
CapEx
$-252,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.11
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,876,163,000
Inventory
$123,604,000
Receivables
$53,503,000
ST Investments
$238,206,000
EBIT TTM
$-37,378,000
Pretax Income TTM
$-67,612,000
Interest Exp TTM
$30,234,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$204,559,008
EBITDA
$-34,799,000
Free Cash Flow
$-78,371,752
Enterprise Value
$688,634,112
Total Cash
$300,848,992
Total Debt
$122,144,000
Shares Out
642,473,409
Trailing EPS
$-0.11
Book Value
$0.34
ROE
-28.3%
ROA
-4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 183,881,000 | -51,553,000 | -83,500,000 | 570,540,000 | 344,668,000 | 225,872,000 | -111,037,000 |
| Dec 2024 | 76,994,000 | -173,732,000 | -174,572,000 | 593,781,000 | 313,461,000 | 280,320,000 | -218,618,000 |
| Dec 2023 | 237,000 | -193,944,000 | -184,127,000 | 394,076,000 | 146,127,000 | 247,949,000 | -167,743,000 |
| Dec 2022 | 596,000 | -138,550,000 | -141,901,000 | 190,575,000 | 110,577,000 | 79,998,000 | -127,379,000 |
TTM Snapshot
Revenues TTM
$30,351,000
NetIncome TTM
$-67,307,000
OpCashFlow TTM
—
Assets (Latest)
$534,120,000
Forward EPS
$0.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OBX | Obsidian Therapeutics, Inc. | $803.05M | $13.00 | — |
| APMD | Apnimed, Inc. | $771.00M | $18.52 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $808.34M | $38.30 | — |
| ANNX | Annexon, Inc. | $762.11M | $4.02 | — |
| IVEVF | Inventiva S.A. | $760.63M | $3.22 | — |
News headlines (Yahoo Finance, 1h cache)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-18 20:01 · Yahoo
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
2026-09-13 14:01 · Yahoo
Geron to Present at Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative
2026-08-09 08:11 · Yahoo
Geron (GERN) Q2 2026 Earnings Call Transcript
2026-08-06 04:28 · Yahoo
Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
2026-08-05 19:04 · Yahoo
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
2026-08-05 13:00 · Yahoo
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-14 20:26 · Yahoo
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
2026-10-07 17:30 · Yahoo
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
2026-09-16 13:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.